Rodin Therapeutics: Alkermes Acquires Rodin In Deal Worth Up to $950 Million

Alkermes, an Ireland-based biopharmaceutical company focused on developing medicines for central nervous system (CNS) diseases and oncology, announced it will acquire Rodin Therapeutics, a Boston, MA-based biopharmaceutical company focused on the development of small-molecule therapeutics for sy